Abstract. It has been proposed that the frequent loss of heterozygosity (LOH) of an entire chromosome 17 contig in epithelial ovarian cancers (EOC) is the consequence of the inactivation of multiple tumour suppressor genes on this chromosome. We report the characterization of a 453 Kb 17q25 locus shown previously to exhibit a high frequency of LOH in EOC samples. LOH analysis further defined the minimal region of deletion to a 65 Kb interval flanked by D17S2239 and D17S2244, which contains RHBDF2, CYGB and PRCD as tumour suppressor gene candidates. Tissue specific expression excluded PRCD as a candidate. RHBDF2 was expressed at low levels in the majority of benign and low malignant potential (LMP) tumours, and in a subset of malignant ovarian tumour samples, as compared with primary cultures of normal ovarian surface epithelial cell (NOSE) samples. CYGB was expressed at low levels in the majority of LMP and malignant samples compared with benign and NOSE samples. In contrast to CYGB expression, RHBDF2 was expressed at low or undetectable levels in EOC cell lines exhibiting tumourigenic characteristics and up-regulated in a genetically modified EOC cell line rendered non-tumourigenic. DNA sequence analysis identified variants but no apparent deleterious mutations in either gene. Methylation-specific PCR analysis suggested that promoter methylation of CYGB but not RHBDF2 occurred in 6 of 31 malignant samples. The results combined suggest that RHBDF2 and CYGB may play distinctive roles in ovarian cancer and could be added to the growing roster of chromosome 17 genes implicated in this disease.
Introduction
It is well established that loss of chromosome 17 is a common occurrence in epithelial ovarian cancers (EOCs), as suggested by karyotype and loss of heterozygosity (LOH) studies (1, 2) . This observation, together with complementation studies involving the transfer of chromosome 17 which resulted in reduced tumourigenicity of an EOC cell line (3) , suggest that this chromosome harbours tumour suppressor genes (TSGs). Chromosome 17 contains a number of very well characterized TSGs. The 17p13.1 region harbours TP53, a TSG that is the most frequently mutated gene in EOC samples, particularly in serous ovarian carcinoma (4, 5) , which is the most common histopathological subtype reported for EOC. The 17q21.31 region harbours BRCA1, a TSG that when inherited in a mutated form in an autosomal dominant fashion significantly increases the risk for developing breast and ovarian cancers (6) (7) (8) . Although BRCA1 is very rarely mutated in sporadic disease, the low level of BRCA1 expression reported in EOC samples has been attributed to alteration of its promoter by CpG methylation (9, 10) . In addition to these genes, DPH1 (17p13.3), HIC1 (17p13.3), NF1 (17q11.2), and RARA (17q21.1), have also been proposed to function as TSGs in EOC (11) (12) (13) (14) . Unique loci exhibiting a high frequency of LOH have also been identified, suggesting the possibility of new TSGs in ovarian cancer (15) (16) (17) (18) (19) (20) (21) (22) . It is thus likely that several genes act in concert in suppressing tumourigenicity and thus account for the unusually high frequency of LOH that often involves an entire chromosome 17 contig in ovarian cancer.
Using LOH analyses we reported a 453 kilobase (Kb) minimal region of deletion (MRD) at 17q25.1-q25.2 that is defined by microsatellite markers D17S1817 and D17S751 (22) . This genomic region contained nine known or strongly predicted genes where rhomboid 5 homolog 2 (Drosophila) (RHBDF2, formerly FLJ22341) and cytoglobin (CYGB) emerged as strong TSG candidates based on decreased gene expression in malignant ovarian cancers (22) . Of note, our candidate interval overlaps the familial tylosis with esophageal cancer locus (23) . Although mutation analyses of RHBDF2 and CYGB did not identify any disease associated mutations, decreased expression of CYGB was observed in familial tylosis with esophageal cancer samples and cell lines derived from sporadic squamous cell esophageal carcinomas (23) (24) (25) (26) . Further characterization of CYGB showed alterations in promoter CpG methylation in sporadic, but not familial tylosis with esophageal cancer (26) . Altered promoter methylation, which in some cases correlated with decreased expression of CYGB, has also been observed in oral squamous cell carcinomas and non-small cell lung carcinomas (NSCLC) (27) (28) (29) (30) . Thus, CYGB appears to be emerging as a strong TSG candidate. RHBDF2 has not been investigated in cancers to the same extent, and thus its role in cancer is unknown (22) (23) (24) .
In the present study we have further characterized the 17q25.1-25.2 MRD and excluded all but three of the nine TSG candidates mapping to this region in ovarian cancer. These three genes are RHBDF2 and CYGB, our top TSG candidates from our initial study of the chromosome 17q25 region in ovarian cancer (22) , and PRCD (progressive rod-cone degeneration), previously known as AK054729, an expressed sequence tag of unknown function (22) . We have investigated gene expression in an expanded panel of serous histopathological subtype ovarian cancer samples and various EOC cell lines exhibiting differences in tumourigenic potential, as well as extended our analysis to include benign and low malignancy potential (LMP) or borderline ovarian tumours of the serous subtype. We have also investigated gene expression of an EOC cell line rendered non-tumourigenic as a consequence of chromosome transfer from our group (31) . The genetically modified EOC cell line was investigated to determine if the observed reprogramming (alteration in the transcriptome) of key genes involved in ovarian cancer (31, 32) that has occurred as a consequence of tumour suppression also included 17q25 candidates identified in our LOH analyses. To begin to investigate mechanisms of altered gene expression, we have performed DNA sequencing and promoter methylation assays.
Materials and methods
Ovarian tumour samples. Tumour samples and peripheral blood lymphocytes were collected with informed consent from participants undergoing surgeries performed at the Research Centre of the University of Montreal Hospital Centre (CRCHUM)-Notre Dame Hospital site or from surgeries performed at the McGill University Health Centre -Montreal General Hospital as described (21, 33) . Clinical features such as disease stage, and tumour characteristics such as grade and histopathological subtype, were assigned by a gynecologiconcologist and/or gynecologic-pathologist according to the criteria established by the International Federation of Gynecology and Obstetrics as reported in previous studies for some cases (21, 22, 34) and summarized in Table I .
Primary cultures of NOSE samples. Primary cultures were derived from normal ovarian surface epithelial (NOSE) cells from the ovaries of eight participants with no prior history of ovarian cancer, following prophylactic oophorectomy at the CRCHUM Notre Dame Hospital site, and were established as described previously (33) (34) (35) . Cells were cultured in OSE Medium supplemented with 2.5 µg/ml amphotericin B, 50 µg/ ml gentamicin and 15% fetal bovine serum (FBS) as previously described (34) . EOC cell lines were derived from a stage IIIc/  grade 1-2 papillary serous adenocarcinoma (TOV-81D), a  stage III/grade 3 clear cell carcinoma (TOV-21G), a stage IIIc/  grade 3 endometrioid carcinoma (TOV-112D) , the ascites fluid of a stage IIIc/grade 3 adenocarcinoma (OV-90), a stage IIIc/ grade 3 serous carcinoma (TOV-2223G), and both the tumour and the ascites fluid of a stage IIIc/grade 3 serous tumour (TOV-1946 and OV-1946) , all from chemotherapy naïve patients, as described (36, 37) . The non-tumourigenic chromosome 3 transfer radiation hybrids (RH), RH-5, RH-6, and RH-10 cell lines, were derived using a neomycin clone of OV-90 (OV-90 neo r ), and the B78MC166 mouse cell line containing human chromosome 3 as described previously (31) . The cell lines were cultured in OSE Medium supplemented with 2.5 µg/ml amphotericin B, 50 µg/ ml gentamicin and 10% FBS as described previously (36, 37) .
EOC cell lines.
Nucleic acid extraction. DNA was extracted from clinical specimens, peripheral blood lymphocytes, and EOC cell lines, as described previously (31, 33) . Total RNA was extracted with TRIzol™ reagent (Gibco/BRL, Life Technologies Inc., Grand Island, NY) from the primary cultures of NOSE samples, and the EOC cell lines, grown to 80% confluency in 100 mm Petri dishes, and from frozen ovarian tumour samples as described previously (31, 38) . RNA quality was assessed by gel electrophoresis and 2100 Bioanalyzer analysis using the Agilent RNA 6000 Nano kit.
LOH analysis. The polymorphic microsatellite repeat markers, D17S2238, D17S2239, D17S2244, D17S2245 and D17S2246, were used in LOH analysis. The genomic location of the markers was based on the March 2006 human reference sequence (NCBI Build 36.1/hg18) assembly (39) . LOH was performed using a PCR-based assay essentially as previously described (22, 40) using primer sets and annealing temperatures described by Langan et al (23) . LOH (or allelic imbalance) was scored based on the absence or difference in the relative intensity of alleles in tumour DNA compared with the DNA extracted from patient-matched peripheral lymphocytes.
Gene expression analyses.
A semi-quantitative RT-PCR assay of cDNA was used to assess gene expression essentially as described (22, 31, 41) . About 200 ng of a 1:10 dilution of the reverse transcribed cDNAs were used in PCR assays with genespecific primers (Table II) . Primers were designed using Primer3 software (42) based on the genomic structures of RHBDF2 and PRCD available from the March 2006 human reference sequence (NCBI Build 36.1/hg18) assembly (39) , and alignment of reference sequences NM_024599 and NM_001077620, of each gene, respectively. The primers for CYGB were designed as described previously (22) . The RT-PCR-based assays were performed essentially as previously described (43) . The PCR conditions were 3 min at 95˚C, 30 cycles of 94˚C for 30 sec, annealing temperatures for 30 sec and 72˚C for 30 sec. Products were electrophorosed on a 1% agarose gel, visualized by ethidium bromide staining and RNA quality was assessed by 18S expression (25 PCR cycles). RT-PCR analysis was also performed on cDNA prepared from commercially available TOV944  GT  TOV  67  IIIc  Serous papillary  +  +  +  22  TOV947  D  TOV  53  Ia  Serous papillary  +  +  +  22  TOV921  GT  TOV  55  IIIc  Endometrioid  +  +  +  22  TOV962  T  TOV  55  IIIc  Endometrioid  +  +  +  22  TOV858  GT  TOV  59  IIIc  Endometrioid  +  +  +  22  TOV863  DT  TOV  72  IIIc  Endometrioid  +  +  22  TOV760  T  TOV  73  IIIc  Clear cell  +  +  +  22  TOV903  D  TOV  48  IIIc  Serous papillary  +  +  +  22  1167  T  TOV human normal ovary, testes, and placenta RNAs (Stratagene, La Jolla, CA) and human retina total RNA (Clontech, Mountain View, CA). Primer sequences and annealing temperatures are shown in Table II , primer sequences for 18S were reported previously (22) . Affymetrix GeneChip U133 Plus 2 analysis of RHBDF2 and CYGB was extracted from the transcriptome analyses performed for OV-90neo r and the non-tumourigenic chromosome 3 transfer radiation hybrids, RH-5, RH-6, and RH-10 cell lines, described previously (31) .
Genomic sequencing analyses. Sequencing analysis was performed on PCR products representing the protein coding exons and flanking splice sites of RHBDF2 and CYGB derived from genomic DNA extracted from the EOC cell lines and ovarian tumour samples. Primers designed to analyze RHBDF2 and CYGB were initially based on their respective reference sequences NM_024599, and NM_134268, as aligned to the genomic structure of each gene according to the March 2006 (NCBI36/hg18) assembly. Although the location of each gene has changed the annotation has been maintained in the most recent [February 2009 (GRCh37/hg19)] assembly of the human genome (44, 45) . The primers were designed using Primer3 software (42) . The PCR assays were carried out as previously described (43) . Primer sequences and PCR annealing temperatures are found in Table II . The PCR products were sequenced in both directions using the 3730XL capillary DNA Analyzer system platform from Applied Biosystems at the McGill University and Genome Quebec Innovation Center, Montreal, Canada as previously described (43) . Sequence chromatograms from both directions were aligned and compared with the RHBDF2 and CYGB reference sequences. Sequence variants were compared with those reported in the Single Nucleotide Polymorphism (dbSNP) database (www.ncbi.nlm.nih.gov/ projects/SNP/) (46) . The variants resulting in amino acid substitutions were examined by PolyPhen (genetics.bwh.harvard.edu/ pph) (47), Panther (www.pantherdb.org/tools/csnpScoreForm. jsp) (48) , SNPeffect (snpeffect.vib.be) (49), F-SNP (compbio. cs.queensu.ca/F-SNP/) (50) and SIFT dbSNP (sift.jcvi.org/ www/SIFT_dbSNP.html) (51), and aligned to orthologous genes from various species using the UCSC Genome Bioinformatics Site (genome.ucsc.edu) in order to predict the possible impact on the structure and function of the encoded protein (45) .
Allele frequencies of sequence variants. DNA sequence analysis of the EOC cell lines identified the RHBDF2 variants 2064A>G and 492G>T. Allele frequencies of these variants were determined by comparing genotypes of peripheral blood lymphocytes from 111 healthy women and 104 ovarian cancer cases. The samples were collected with informed consent from the CHUM at Notre Dame Hospital.
PCR-based assays were used to detect the presence of the variants using primers and annealing temperatures described in Table II . The 2064A>G variant, located in exon 15, was detected by single-strand conformation polymorphism (SSCP) analysis using previously described conditions (40) . Briefly, the reaction products were diluted 2:3 with stop buffer and heated at 95˚C for 15 min before loading on a 30% acrylamide nondenaturing gel. The products were electrophoresed at 20 W for 15 min followed by 3 W for 18 h at room temperature. Gels were dried and autoradiographed. Variants were detected as a band shift and compared with patterns from a variant-positive EOC cell line. The 492G>T variant, located in exon four, was detected using a PCR-based restriction fragment length polymorphism (RFLP) assay. The variant alters the sequence that would normally be recognized and cleaved by the HpyCH4V restriction endonuclease. PCR products were digested overnight at 37˚C and resolved by agarose (1%) gel electrophoresis. Allele and genotype frequency distributions were compared by Pearson's Chi-square test (Statistical Product and Service Solution Package, SPSS, Chicago, IL).
DNA methylation analysis. Hypermethylation of the putative promoter regions of RHBDF2 and CYGB were examined using methylation specific PCR assays following bisulfite conversion of cytosine residues. The bisulfite conversion reactions were performed using the Imprint™ DNA Modification kit (SigmaAldrich Canada Ltd., Oakville, Ontario) with 1 µg of DNA from the EOC cell lines and ovarian tumour samples. The methylation specific primers for CYGB were designed using the MethPrimer program (52) to overlap genomic regions previously investigated for methylation (27) . The primers for RHBDF2 were also designed using MethPrimer, based on a putative CpG island that maps 123 Kb upstream of the gene, and overlaps the first exon (39) . The PCR reactions were carried out as previously described (43) . In the absence of CYGB and RHBDF2 methylated control, CDKN2A was investigated to assess bisulfite conversion in all assays as it has been shown methylated in the TOV-112D EOC cell line (13) . Primer sequences and annealing temperatures can be found in Table II .
Results

Defining the 17q25 TSG locus.
A previous LOH analysis identified a 453 Kb minimal region of deletion defined by the microsatellite markers D17S1817 and D17S751 which contained nine known or strongly predicted genes and two ESTs (22) . Recent annotations of the human genome have further defined this interval with the addition of genes predicted to encode small nucleolar RNAs (Fig. 1A) . To further define this region of deletion and select TSG candidates for molecular genetic analyses, LOH analysis was performed on the subset of 16 malignant ovarian cancer samples and two LMP samples previously shown to contain interstitial deletions (22) . Since our report, microsatellite markers D17S2238, D17S2239, D17S2244, D17S2245 and D17S2246 were identified, but upon further testing only D17S2239 and D17S2244 were found to be informative for LOH analyses (Fig. 1B) . The LOH results are summarized along with previously published reports for the analysis of markers D17S1817, D17S801 and D17S751 (reproduced in Fig. 1B) . Taken together, these data further refined the MRD to an estimated 65.08 Kb interval flanked by the markers D17S2239 and D17S2244 based on the February 2009 human reference sequence (GRCh37) (45) . The MRD was observed in malignant tumours of the serous, endometrioid, clear cell and mucinous EOC histopathological subtypes. Notably, ovarian cancer samples 1167T and OV747 exhibited LOH only for D17S801. This newly refined candidate TSG-containing locus contains the entirety of CYGB and PRCD, as well as the first exon of RHBDF2.
Gene expression analyses. The LOH analysis identified RHBDF2, CYGB and PRCD as top TSG candidates, as ST6GALNAC2, ST6GALNAC1, MXRA7, JMJD6, METTL23, SFRS2, ET, MFSD11 and MGAT5B fell outside of the newly defined minimal region of deletion (Fig. 1A) . We previously showed low or absent expression of RHBDF2 and variable expression of CYGB in malignant ovarian cancer samples exhibiting LOH of the 17q25 locus including D17S801 relative to primary cultures of NOSE (22) . To further characterize the gene expression of our candidates, and as PRCD was not previously investigated, we have extended this analysis to include a larger panel of NOSE samples and malignant ovarian cancer samples and also included an investigation of benign and LMP ovarian tumours. All ovarian tumour samples investigated were histopathologically classified as serous, which represents the most common subtype of epithelial ovarian cancers. We performed semi-quantitative RT-PCR analyses as our studies have consistently shown a very good concordance of gene expression when compared with more quantitative methods such as gene expression microarray analyses or quantitative RT-PCR in comparing primary cultures of NOSE samples, benign and LMP tumours, and malignant ovarian cancer samples and our EOC cell lines, where overt differences in gene expression were detectable in these ovarian cancer model systems of study (22, 32,34,41,53,54 ). PRCD expression by RT-PCR analysis was not detectable in NOSE samples, malignant ovarian tumour samples or from ovary, testes or placental tissues ( Fig. 2A ). However, low-level expression was detectable in retina, which is consistent with independent reports showing PRCD expression in retina and retinal pigment epithelium/choroids (55) . In contrast, RHBDF2 and CYGB expression was detectable by RT-PCR in NOSE, benign and LMP tumour samples, and malignant ovarian cancer samples (Fig. 2B) . RHBDF2 expression was detectable in all NOSE samples. In contrast, RHBDF2 was expressed at low or undetectable levels in the majority of benign and LMP samples, and a subset of malignant samples. The low or undetectable levels of RHBDF2 expression in a subset of malignant ovarian cancer samples (particularly TOV800EPT, TOV881MT, TOV908DT, TOV974EPT, and TOV1007EPT) is consistent in part with our previous study where expression was not detectable in malignant ovarian cancer samples of different histopathological subtypes (endometrioid, clear cell, mucinous and serous) where all exhibited LOH of the D17S801 locus (Fig. 1B) (22) .
Of note, some of the malignant ovarian cancer samples exhibiting low levels of RHBDF2 expression, such as TOV800EPT, TOV881MT and TOV908DT, also harbor LOH (or allelic imbalance) of the D17S801 locus as determined in an independent study from our group (34) (Fig. 2B) . Although CYGB expression was also detectable in all NOSE samples, expression was clearly detectable in all benign ovarian tumour samples (Fig. 2B) . CYGB expression was low or undetectable in the majority of LMP samples and in all malignant ovarian cancer samples (Fig. 2B) . As the same batch of cDNAs were used in the semi-quantitative RT-PCR analyses, the expression profiles likely reflect differential expression of RHBDF2 and CYGB in ovarian tumour samples as has been observed in our previous studies with other genes (22, 32, 34, 41, 53, 54) . RHBDF2 and CYGB expression was also detectable in whole ovary, testes and placenta. Given the apparent tissue specific expression of PRCD and absence of ectopic expression in NOSE and ovarian tumour samples ( Fig. 2A) , we excluded this gene from further investigation as a TSG candidate.
Gene expression analysis of RHBDF2 and CYGB was also investigated by semi-quantitative RT-PCR in EOC cell lines established as long-term passages from chemotherapy naïve ovarian cancer samples in our research group (36, 37) . The cell lines differ in their in vivo tumourigenic potential, where TOV-81D and TOV-2223G are incapable of forming tumours as xenografts in immunocompromised mice in contrast to OV-90, TOV-21G, TOV-112D, TOV-1946, and OV-1946 (36,37) . However, in contrast to TOV-81D, TOV-2223G retains some in vitro features of tumourigenic cells, such as the ability to invade matrigel and form colonies in soft agarose (37) . By semi-quantitative RT-PCR or gene expression microarray analyses, TOV-81D has also been shown to retain gene expression profiles that resembled NOSE samples (22, 32, 34, 41, 53, 54) . Notably, TOV-81D exhibited the highest level of expression of RHBDF2 whereas low or undetectable levels of expression were observed in all of the other EOC cell lines (Fig. 3A) . Although CYGB expression was also robust in the TOV-81D cell line, expression was also clearly detectable in OV-90, TOV-21G and TOV-2223G. As these EOC cell lines differ in their allelic content of the D17S801 locus (Fig. 3A) , it is possible that differences in gene expression in some of the EOC cell lines could be due to dosage effects.
Expression analysis was also performed on the OV-90 derivative cell lines, RH-5, RH-6 and RH-10, rendered nontumourigenic as a consequence of chromosome 3 fragment transfer (31). These cell lines were derived in the context of research involving the identification of chromosome 3p TSGs (31, 54) . Affymetrix gene expression analyses showed an altered transcriptome in comparison to the parental OV-90 cell line, wherein some genes were reprogrammed and reflected the expression profile observed in NOSE samples as compared with malignant ovarian cancer samples (31, 32) . Affymetrix gene expression analysis showed a consistent up-regulation of RHBDF2 expression in the three independently derived nontumourigenic OV-90 hybrid cell lines RH-5, RH-6 and RH-10 but no detectable difference in CYGB expression as compared with the tumourigenic parental cell line OV-90 (31) (unpublished data). These observations are consistent with RT-PCR results (Fig. 3B) .
Sequence analysis of RHBDF2 and CYGB. A classical mechanism of inactivation of tumour suppressor genes involves the loss of one parental allele possibly through chromosome nondisjunction and somatic mutation of the remaining parental allele. We investigated the possibility of somatic inactivation by sequencing the genomic DNA regions that represent the protein coding exons and splice junction sites of RHBDF2 and CYGB. We began our analysis by investigating the EOC cell lines as some of these cell lines exhibited allelic imbalance or loss of heterozygosity of the 17q25 locus containing the gene candidates. Relative to the reference sequences of each candidate gene, sequence variants were identified in both genes, in all EOC cell lines (Table III) . In sequencing RHBDF2, we identified three sequence variants that confer an amino acid substitution, one variant in the gene's 5'UTR, and four variants in intronic regions. The variants 492G>T, 916C>T and 2064A>G result in the amino acid substitutions A67S, P208L, and M591V, respectively. Sequencing CYGB resulted in the identification of two intronic variants, and two adjacent variants that are situated in the 3'UTR. With one exception, all variants identified have been reported in the dbSNP database (www.ncbi.nlm.nih.gov/projects/SNP) (46) ( Table III) . The CYGB 697-79C>T variant identified in both TOV-1946 and OV-1946, which are cell lines derived from the malignant tumour and ascites sampled from the same patient (37), has not been reported previously. None of the identified intronic variants are close to splice sites, or create novel consensus GTAG splice site sequences.
We then extended our sequence analysis to the ovarian tumour samples that exhibited LOH of the D17S801 locus (22), of which all but one was available for this analysis (Table IV) . Eight of the 11 sequence variants identified in the EOC cell lines were also identified in the tumour samples, and no other sequence variants unique to these tumour samples were observed.
Frequencies for northern and western European populations (CEU) are available for 5 of the 11 reported SNPs (Table III) . Data for this population was reviewed as our cancer samples and derived cell lines were ascertained from the French Canadian population of Quebec, a population sharing common European ancestry (56) . Notably, the CEU population frequency of RHBDF2 916C>T variant, conferring a P208L amino acid change, is 100% for the T allele, which is consistent with our results for all EOC cell lines, suggesting that this is the most common allele in the population. Population frequencies for the RHBDF2 variants 492G>T and 2064A>G, that are both predicted to result in amino acid substitutions, are not reported Table III in dbSNP. Consequently, we determined the genotype and allele frequencies in peripheral blood lymphocyte DNA from healthy women and women affected with ovarian cancer representative of our population. There were no significant differences in the genotype and allele frequencies between unaffected and affected women for either variant (p=0.06-0.76) ( Table V) .
The RHBDF2 variant 492G>T (in exon 4) is predicted to result in the substitution of a nonpolar alanine residue with the polar serine residue at amino acid position 67, whereas the variant 2064A>G (in exon 15) results in the substitution of a methionine with a valine residue which are both basic amino acids. The predicted structure of RHBDF2 is that of a seven helical transmembrane protein with an extended intracellular N terminus and a highly conserved loop region, termed the iRhom homology domain (IRHD), that is found between the first and second transmembrane domains (57) . According to this structure, the A67S substitution would affect an amino acid located in the intracellular N terminus domain of the protein, whereas the M591V substitution would affect the amino acid sequence of the highly conserved IRHD. In applying various computational tools that predict the functional effects of sequence variants, neither substitution was predicted to have a biological impact on the encoded protein (see Materials and methods).
As evolutionarily conserved amino acids may be indicative of functionally important residues, we also investigated the conservation of amino acid sequences encoded by 492G>T (A67S) and 2064A>G (M591V) using the UCSC genome browser vertebrate multiz alignment and conservation (44 species) track (45) . Both variants and their flanking amino acid sequences appear to be conserved in primates (Fig. 4) . The A67S variant, and flanking amino acid sequences, appear not to be well conserved beyond primates (Fig. 4) . The M591V variant, and flanking amino acids also appear to be conserved in other placentals and vertebrates including the rabbit, the dolphin and the chicken (Fig. 4) .
Methylation analyses of CYGB and RHBDF2.
Loss of gene function in cancer cells can also be achieved by affecting the regulation of gene expression by methylation of CpG regions in the promoter regions of tumour suppressor genes. Although previous studies have shown methylation of CYGB in other cancer types (26) (27) (28) , methylation of CYGB promoter regions has not been investigated in the context of ovarian cancer. Moreover, to our knowledge, promoter methylation of RHBDF2 has not been investigated in any cancer context. We applied methylation-specific PCR analysis to investigate the possibility of altered CpG methylation in the inferred promoter regions of CYGB and RHBDF2. As we did not have any samples exhibiting methylation of these genes, we also included a 
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NA, DNA no longer available to perform assay; LMP, low malignant potential; T, tumour; D/DT, tumour on right ovary; GT, tumour on left ovary. Table V . Allele frequency analysis of RHBDF2 variants 492G>T and 2064A>G. Group  Total  GG  GT  TT  Total  G  T  ( The methylation specific PCR results show the presence of a doublet, which could perhaps be attributed to the high GC content of the amplified region. Methylation-specific PCR assays however, did provide evidence of methylation in the OV-1946 EOC cell line (Fig. 5A) . These results are interesting given that both OV-1946 and TOV-1946 cell lines exhibited undetectable levels of CYGB expression (Fig. 3A) . They were derived from malignant ovarian ascites (OV-1946) and tumour (TOV-1946) samples from the same ovarian cancer patient (37) . Both cell lines exhibited LOH of the 17q25 locus (Fig. 3A) , and likely share the same alleles as suggested by DNA sequencing analysis (Table III) . Moreover, these cell lines have been shown to exhibit similarities in their molecular genetic features (such as sharing a common somatic TP53 mutation), growth characteristics and tumourigenic potential (37) . Although we cannot exclude the possibility of tissue culture effects, these observations combined suggest that alteration in methylation status of OV-1946 was unlikely to occur as an early event in the evolution of ovarian cancer disease in the patient from which these EOC cell lines were derived.
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We then investigated the malignant ovarian cancer samples, LMP and benign ovarian tumours that were examined by gene expression analysis, to determine if the low or undetectable levels of expression observed could be due to alteration of promoter methylation. Genomic DNA was available for a subset of malignant ovarian cancer samples investigated by semi-quantitative RT-PCR analyses in the present study (Figs. 5B, and 2B ). In addition, genomic DNA was also available for a subset of malignant ovarian cancer samples examined for gene expression in our previous analysis of 17q25 candidates, which were shown to exhibit LOH overlapping the 17q25 locus (Fig. 5B) . In an earlier study, we reported no detectable expression of RHBDF2 in these samples, although CYGB expression was detected in TOV944GT, TOV760T and TOV903D (22) . Although there was no evidence of promoter methylation for the benign and LMP tumour samples (Fig. 5C ), six malignant ovarian cancer samples TOV881MT, TOV974EPT, TOV1095DT, TOV1108DT, TOV1127GT and TOV1142DT exhibited evidence of promoter methylation of CYGB (Fig. 5B) . These results are interesting given the low or undetectable levels of CYGB expression observed in all samples analyzed in the present study (Fig. 2B) . All of the samples exhibiting evidence of methylation silencing are of the serous histopathological subtype of ovarian cancer (Table I) . Given the unexpectedly high frequency of methylation results in the analysis of CYGB, we extended our analysis of CYGB (as well as RHBDF2 and CDKN2A) to the malignant ovarian cancer samples exhibiting interstitial loss of the 17q25 locus that was limited to the minimal region of deletion (Figs. 5D, and 1B) and a new panel of malignant ovarian serous subtype cancer samples (Fig. 5D) . We observed no other examples of CYGB methylation in these samples. Thus we observed CYGB promoter methylation in 6 of 31 malignant ovarian cancer samples, where 6 of 25 (24%) samples examined share in common the serous histopathological subtype classification.
Discussion
LOH mapping further refined a 65 Kb overlapping region of deletion containing three known protein-encoding genes, RHBDF2, CYGB and PRCD to pursue as TSG candidates in the context of ovarian cancer. The absence of PRCD expression in normal and tumour ovarian tissues combined with reported tissue-specific expression in retinal cells (55) suggests that this gene is unlikely to play a role in ovarian cancer. In contrast, the differential expression of both RHBDF2 and CYGB in malignant ovarian cancer samples and EOC cell lines suggests a possible role in this disease. Low or undetectable levels of RHBDF2 expression were apparent in a subset of malignant ovarian cancer samples relative to NOSE samples. Whereas low or undetectable expression of CYGB was more clearly apparent across all samples analyzed. Although these results are consistent with our previous studies (22) , low or undetectable levels of expression of RHBDF2 were also apparent in other histopathological subtypes than that observed with CYGB expression. This suggests a role for RHBDF2 in a subset of malignant ovarian cancer samples and perhaps a more extensive role for CYGB, particularly in the serous histopathological subtype.
An interesting observation is the decreased or absent expression of RHBDF2 in EOC cell lines that exhibit various in vivo and in vitro features associated with tumourigenic potential. The apparent up-regulation of RHBDF2 in the OV-90 EOC Figure 5 . Methylation specific PCR analysis of CYGB and RHBDF2. Methylation specific PCR assays of RHBDF2 and CYGB were performed on bisulfitetreated DNA with primers designed to detect methylated (M) or unmethylated (U) sequences. Methylation specific analysis was also performed for CDKN2A, shown previously to exhibit methylation in the TOV-112D EOC cell line, to control for bisulfite conversion. Shown are results from EOC cell lines (A); the malignant ovarian serous cancers also examined for gene expression in the present study and the previous studies where samples TOV944GT, TOV947D, and TOV903D represent serous histopathological subtype cases (B); the LMP and benign ovarian tumours examined for gene expression in the present study (C); and the samples shown to exhibit interstitial loss of 17q25 locus where samples TOV701T and TOV747NC (not cultured) represent serous histopathological subtype cases, and a new set of malignant ovarian cancers of the serous histopathological subtype (D).
cell lines rendered non-tumourigenic as a result of transfer of a normal copy of chromosome 3 also suggests an association of gene expression with tumourigenicity (31) . Thus, RHBDF2 may be one of a number of genes transcriptionally reprogrammed as a consequence of tumour suppression (32) . RHBDF2 underexpression could not be attributed to somatic mutations or alteration of promoter methylation status, mechanisms that have been shown to inactivate or alter TSG function (58) . Thus alternative epigenetic mechanisms deregulating RHBDF2 expression are involved, and this is also inferred by our transcriptome analyses of the genetically modified OV-90 cell line (31, 32) . In contrast to RHBDF2, differential expression of CYGB in the EOC cell lines was observed and there was no alteration in gene expression profile in the genetically modified OV-90 derived EOC cell lines. However, it is interesting to note the undetectable levels of CYGB expression in TOV-1946 and OV-1946 EOC cell lines relative to TOV-81D and TOV-2223G, given that these cell lines were all derived from ovarian cancers of the serous histopathological subtype, and that the former exhibit both in vitro and in vivo characteristics associated with tumourigenic potential (36, 37) . It is possible that the CYGB expression profile is more characteristic of malignant ovarian carcinomas of the serous histopathological subtype as has been observed for other genes differentially expressed in serous ovarian cancer (32) . Although dysregulation of CYGB expression could not be attributed to somatic mutations, alteration of promoter methylation status was observed in some malignant ovarian cancer cases.
An interesting observation is that methylation was observed in malignant samples of the serous histopathological subtype. Although alteration of promoter methylation is suggestive of a mechanism of dysregulating CYGB expression, not all samples exhibiting undetectable levels of CYGB expression exhibited evidence of promoter methylation by the methylation-specific PCR-based assay. As independent studies of CYGB applied a pyrosequencing-based methylation analysis of cancer samples (a methodology not feasible in the present study) (26) (27) (28) 30) , which investigates quantitatively the degree of methylation at CpG positions in close proximity to the promoter, it is possible that methylation of CYGB is more extensive than detected in our analysis or alternatively not associated with alteration in gene expression. Future studies examining a large number of malignant ovarian carcinomas would be required to determine the association of CYGB expression and methylation status, and its extent in malignant ovarian cancer, particularly in the serous histopathological subtype of this disease.
The refined TSG locus resides in a region containing high GC and Alu repeat content, the latter of which has been associated with regions prone to deletions or rearrangements (59, 60) . Another interesting structural feature of our candidate region is that it contains a 1.5 Kb inverted, duplicated sequence, that spans 13 Kb and includes the polymorphic microsatellite marker D17S801 (22) We have proposed that this structure may contribute to the instability of the genomic region and thus account for the high frequency of LOH of D17S801 in ovarian cancer specimens (22) . Although our refined region also contains SNORD1A, SNORD1B, and SNORD1C, which encode small nucleolar mRNAs that are predicted to guide the 2'O-ribose methylation of 28S rRNA G4362 (61), and LOC100507246 (62), the SNORD1 genes have been provisionally mapped and LOC100507246 is a recently annotated hypothetical gene for a non-coding RNA of unknown function, neither of which have been implicated in cancer.
An interesting observation was the differential expression pattern of RHBDF2 and CYGB in benign versus LMP serous subtype ovarian tumours. Low or undetectable levels of RHBDF2 expression were observed in the majority of benign and LMP ovarian tumours relative to the NOSE samples. CYGB was expressed in all benign samples but showed low or undetectable gene expression levels in the majority of LMP tumours. There is mounting evidence that the serous histopathological subtype of ovarian cancer develops along multiple pathways. In one pathway, tumours develop in a stepwise manner, from a benign lesion to an LMP tumour and finally to a low-grade malignant serous subtype tumour (63) . In an alternate pathway, high-grade serous tumours arise without a recognizable precursor or intermediate lesion (63) . Comparative genomic hybridization analyses have identified chromosome 17 loss in both LMP and stage I invasive tumours, suggesting chromosome 17 loss to be an early event in the development of serous ovarian cancers or characterizes those LMP tumours that are likely to become invasive (64) . Noteworthy, of the 11 LMP tumour samples investigated in our initial LOH analysis of chromosome 17 (21) , only one sample exhibited LOH and this sample exhibited loss of the 17q25.1 region. The frequency of LOH of the 17q25.1 locus is in keeping with the observations in the present study where only two of nine LMP samples (2559T and TOV696T) exhibited LOH of the 17q25.1 locus (22) . LMP cases are often managed by surgical intervention resulting in excellent outcomes, however recurrences have been reported in ~15% of cases often with poor outcomes (65, 66) . The long-term survival outcome of our LMP cases with LOH of 17q25.1 is not known, however it would be interesting to determine if the presence of LOH in this chromosomal region is associated with recurrence and/or poor outcome of LMP cases.
CYGB encodes cytoglobin; a highly conserved member of the vertebrate globin family (67, 68) and its role in cancer has not been elucidated. Although CYGB expression has been observed in various tissues, it is mainly expressed in epithelial cells (69) . There is evidence to suggest that CYGB is involved in response to hypoxia, and/or protecting cells from oxidative stress. The genomic regions that encode the 5'UTR and 3'UTR and the putative promoter region of CYGB, contain hypoxia response elements (HRE) and hypoxia-inducible protein binding sites (HIPBS) (70, 71) . Of note, DNA sequencing analysis of CYGB in the present study identified an alteration of adjacent SNPs 739_740 AA > CC in 3 of the 7 EOC cell lines that do not express CYGB. These SNPs, which were observed in a homozygous state, lie between two putative conserved HIPBS motifs that are purported to stabilize the mRNAs of various hypoxiaresponsive genes (70, 72) . The functional consequences of the SNPs are unknown but warrant further investigation given their location within the conserved HIPBS motifs.
In addition, CYGB has been shown to be upregulated by the HIF-1 transcription factor (71) . Hypoxia followed by reoxygenation causes overproduction of reactive oxygen species (ROS), and there is evidence to suggest that CYGB may protect cells against these ROS under conditions of limited oxygen supply by acting as a ROS scavenger (73, 74) . As cancer cells are exposed to oxidative stress (75, 76) , it is possible that CYGB may func-tion as a ROS scavenger in a developing tumour, and loss or decreased CYGB expression may contribute to tumourigenesis. Recently, it was shown that ROS exposure of the MCF-7 breast cancer cell line resulted in the induction of CYGB expression as well as cell cycle arrest and apoptosis (77) . It is also interesting to note that in our previous chromosome 17 transcriptome analyses, a number of genes reported to be hypoxia-related were underexpressed in EOC tumours relative to NOSE samples (34) .
In a cancer context, CYGB has been implicated as a TSG in familial tylosis with esophageal cancer and sporadic squamous cell esophageal carcinoma (23) (24) (25) (26) , and there is preliminary evidence suggesting tumour suppressor activity of CYGB based on the observation of an inverse relationship between CYGB expression and colony formation in NSCLC and breast cancer cell lines (29) . Recently, a CYGB knockout mouse has been generated and it was found that, upon exposure to N,N-diethylnitrosamine, CYGB-deficient mice were more susceptible to liver and lung cancer development, further supporting a role for this gene in cancer (78) . Although the mechanism of dysregulating CYGB expression is unknown, CYGB promoter methylation has been observed in some sporadic squamous cell esophageal carcinomas, oral squamous cell carcinomas, head and neck squamous cell carcinomas and NSCLC that also exhibit low levels of CYGB expression (26) (27) (28) 30) .
Less is known about the function of RHBDF2 and its role in cancer. RHBDF2 (previously called RHBDL6, RHBDL5, and FLJ22341) encodes rhomboid 5 homolog 2 (Drosophila) (also called iRhom2) and belongs to the rhomboid family of proteins. RHBDF2 bears homology to the Drosophila gene rhomboid-1, which encodes an intermembrane serine protease, with seven transmembrane domains and a cytoplasmic amino terminus. Rhomboid-1 is located in the Golgi and functions in the cleavage of Drosophila epidermal growth factor receptor ligands (79) (80) (81) . RHBDF2 (along with RHBDF1) is part of the iRhom subfamily, (57) . Although protein function has not been elucidated, iRhoms resemble other rhomboids but as they lack a catalytic serine-histidine dyad, shown to possess protease function, they have been referred to as the 'inactive rhomboid subfamily'. iRhoms have extended N termini and an IRHD, which is a highly conserved loop region between the first and second transmembrane domains (57) . The function of the IRHD is currently unknown, but it has been suggested that the cysteine residues may form disulfide bridges that could stabilize a globular fold (57) . iRhoms are highly conserved in all animal species, and they may play a regulatory role by binding to and sequestering substrates (81) . Notably, the RHBDF2 sequence variant 2064A>G, which would give rise to the amino acid substitution M591V, is found within the highly conserved IRHD. Although this variant is not predicted to be deleterious according to various computational tools, functional analyses could elucidate its affect on protein activity.
In summary, LOH analysis defined a region of deletion containing RHBDF2, CYGB, and PRCD as candidates to pursue in ovarian cancer. Gene expression analyses of ovarian tumour samples, cell lines and a unique cell line model rendered non-tumourigenic, supports a role for RHBDF2 and CYGB in this disease. However, the differential expression profiles of these genes suggest that their roles may be unique, with RHBDF2 more closely associated with tumourigenic potential. Mechanisms of gene dysregulation appear not to involve intragenic mutations, which would affect protein function. However, promoter methylation silencing may be responsible for dysregulating CYGB expression in some cases. This is the first report of methylation silencing of CYGB in ovarian cancer, suggesting that CYGB may play a role in diverse cancer types, as previous studies have also shown promoter methylation silencing in esophageal and lung cancers (26) (27) (28) 30) . The observation that methylation occurred in the serous but not other histopathological subtypes of EOC is also interesting in light of subtype specific pathways in EOC (82) . It is interesting to note that a recent whole genome sequencing screen of 316 serous ovarian carcinomas identified a case with a missense variant in CYGB and another with a frameshift variant in RHBDF2 (82) . Although large-scale genomic sequencing endeavours are likely to under report variants identified, the results are in keeping with our targeted sequencing endeavours indicating that somatic intragenic mutations may be rare in RHBDF2 and CYGB in ovarian cancer. However, the results raise the question if the RHBDF2 frameshift mutation conferred a selective advantage to the ovarian cancer found to harbour this apparently deleterious mutation. Our results combined suggest that RHBDF2 and CYGB may play distinctive roles in ovarian cancer, could be added to the growing roster of chromosome 17 genes implicated in cancer, and thus warrant further investigation to establish their role in the development of this disease.
